torsemide (torasemide)

03/01/2012 - "Larger clinical trials evaluating torsemide as a first or second-line loop diuretic for congestive heart failure in dogs are warranted."
07/01/2010 - "Clinical trials have indicated that torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failure-related hospitalization. "
08/01/2009 - "This trial will test whether torasemide-PR possesses antifibrotic properties, which may provide an additional benefit beyond diuresis in patients with chronic heart failure."
06/01/2009 - "Previous study showed torasemide, a loop diuretic with anti-aldosteronergic properties, was associated with lower mortality in patients with chronic heart failure (CHF). "
08/01/2002 - "Torasemide in chronic heart failure: results of the TORIC study."

07/09/2009 - "The antihypertensive efficacy of once-daily torasemide PR 5-10 mg was noninferior to that of once-daily torasemide IR 5-10 mg with regard to the change from baseline in sitting diastolic BP (primary endpoint) in a 12-week, randomized, double-blind trial in patients with mild to moderate hypertension. "
12/01/1988 - "Antihypertensive efficacy of low dose torasemide in essential hypertension: a placebo-controlled study."
01/01/1995 - "Thus, additional evidence has accumulated for the clinical efficacy of torasemide in the management of mild to moderate essential hypertension and oedematous conditions which require diuretic therapy. "
01/01/2008 - "Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release."
09/04/1992 - "A series of compounds related to torasemide, a loop diuretic, were synthesized and examined for their diuretic potency and inhibitory activity on the erythrocyte and renal medullary thick ascending limb vesicle Na+,2Cl-,K+ cotransport in Milan hypertensive (MHS) and normotensive (MNS) rat strains, where previous studies had demonstrated an alteration of the cotransport system genetically related to hypertension. "

08/28/2007 - "These findings suggest the hypothesis that the ability of torasemide to reduce myocardial fibrosis in chronic HF patients is related to a decreased PCP activation. "
01/01/1998 - "A greater than normal fraction of torasemide was recovered in the urine of patients with cirrhosis. "
07/01/1993 - "Pharmacokinetic changes of torsemide in cirrhosis therefore compensate for the pharmacodynamic abnormality."
07/01/1993 - "Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis."
08/01/2009 - "The aim of the TORAFIC study is to test the efficacy of torasemide prolonged-release formulation (PR) in reducing myocardial fibrosis in chronic heart failure in a large, randomized clinical trial. "

01/01/1998 - "In chronic renal failure the renal clearance of torasemide decreased in proportion to the decrease of the patients' glomerular filtration rate, whereas the total plasma clearance (3 times that of the renal clearance) appeared to be independent of renal function. "
01/01/1994 - "The results of this study suggest that despite the increased half-life of torasemide metabolites M1, M3 and M5 in end-stage renal failure patients, no accumulation of the parent drug torasemide and its metabolites during chronic dosing is demonstrable."
01/01/1991 - "The results of a study with torasemide given intravenously in healthy subjects and in patients with stable chronic renal failure of various degrees are reported and discussed. "
07/01/1997 - "High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure."
01/01/1994 - "The pharmacokinetics of torasemide, a new loop diuretic, as well as its active metabolites M1 and M3, and its inactive main metabolite, M5, were studied in 12 patients with end-stage renal failure during single i.v. (n = 6) or single oral (n = 6) dosing of 200 mg torasemide, and during chronic oral treatment for 9 days (n = 12). "

01/01/1986 - "The influence of haemodialysis and haemofiltration on the clearance of torasemide in renal failure."
01/01/1986 - "Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency."
01/01/2005 - "Torsemide has a longer duration of action and does not accumulate in renal failure. "
07/01/1997 - "Torasemide appears to be a good choice for the treatment of patients with renal failure."
08/01/1994 - "In a single-blind, randomized, placebo controlled crossover study we compared the natriuretic and chloruretic effect of the loop diuretic, torasemide, given alone or in combination with the thiazide diuretic, butizid, in 10 patients with advanced renal failure (mean CIn 13.1 +/- 5.9 ml/min/1.73 m2). "